Obsidian Therapeutics, Inc.
Obsidian Therapeutics is a biotechnology company developing cell-based and genetic treatments. Its pipeline includes OBX-115, an investigational therapy being studied in advanced solid tumors, including melanoma and non-small cell lung cancer. The company also develops tumor-infiltrating lymphocyte therapies using mbIL15 and its Cytodriver platform, which regulates protein activity with FDA-approved small-molecule drugs. Obsidian Therapeutics is based in Cambridge, Massachusetts.
No SEC Form 4 filings for $OBX in the last 30 days.
See all $OBX insider activity →Healthcare stocks rose on clinical and financial updates. OBX shares gained 38% after reporting positive melanoma therapy data. ONCO rose 32% following a reverse stock split. TMDX advanced 26% on strong Q3 revenue and raised FY26 guidance. DAVI gained 20% with plans for acquisition financing. BCTX rose 10% on preclinical immunotherapy findings.
Obsidian Therapeutics reported updated data for amsoki-cel, a melanoma therapy, showing a 67% objective response rate (10/15 patients) and 33% of patients (5/15) in ongoing response at 12 months. Median progression-free survival was 8.3 months. The therapy demonstrated a favorable safety profile. Topline data from the Phase 1/2 Agni-01 study is expected by year-end 2027. Obsidian is also investigating amsoki-cel in non-small cell lung cancer (NSCLC).
Obsidian Therapeutics (OBX) will present clinical data for its melanoma therapy amsokigene autoleucel at the Society for Immunotherapy of Cancer Annual Meeting in November 2026. The data includes safety and efficacy results from Phase 1 studies in patients with advanced melanoma, with presentations scheduled for November 7.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning OBX (Obsidian Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent OBX coverage spans financial news, technology and market movers.
Positive clinical efficacy and safety read-through likely supports momentum, but investors will still wait for later topline milestones.
Positive trial results suggest strong efficacy and safety, likely boosting investor sentiment.
The upcoming data release could move OBX shares depending on the trial outcomes.
The filing introduces new share supply potential but no immediate proceeds, likely creating modest upside volatility.
Enrollment progress plus prior response-rate results and a large cash raise support a near-term momentum bid, while pushing key readout risk into 2027.
AlphAI scores every news story that mentions OBX with an AI model for sentiment and relevance, and aggregates insider trades from Obsidian Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Healthcare stocks rose on clinical and financial updates. OBX shares gained 38% after reporting positive melanoma therapy data. ONCO rose 32% following a reverse stock split. TMDX advanced 26% on strong Q3 revenue and raised FY26 guidance. DAVI gained 20% with plans for acquisition financing. BCTX rose 10% on preclinical immunotherapy findings.
Obsidian Therapeutics reported updated data for amsoki-cel, a melanoma therapy, showing a 67% objective response rate (10/15 patients) and 33% of patients (5/15) in ongoing response at 12 months. Median progression-free survival was 8.3 months. The therapy demonstrated a favorable safety profile. Topline data from the Phase 1/2 Agni-01 study is expected by year-end 2027. Obsidian is also investigating amsoki-cel in non-small cell lung cancer (NSCLC).
Obsidian Therapeutics (OBX) will present clinical data for its melanoma therapy amsokigene autoleucel at the Society for Immunotherapy of Cancer Annual Meeting in November 2026. The data includes safety and efficacy results from Phase 1 studies in patients with advanced melanoma, with presentations scheduled for November 7.
Obsidian Therapeutics, Inc. (OBX) filed an IPO registration statement for up to 29,164,045 shares of common stock, but this is a resale registration by selling stockholders, not a company sale. The company will not receive proceeds from these resales. Obsidian's common stock began trading on Nasdaq under the symbol 'OBX' on August 4, 2026, with a closing price of $17.04 per share on August 27, 2026.
Obsidian Therapeutics (OBX) shares rose 16.36% to $32.00 after the company enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study for amsoki-cel (OBX-115) in checkpoint inhibitor-resistant advanced melanoma. Obsidian also completed a $350 million private placement, expecting cash to fund operations into 2H 2028.
24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
RTW Biotech Opportunities said Obsidian Therapeutics completed its merger with Galera Therapeutics Inc. via a reverse merger, with a concurrent private financing of about $350m. The combined company began trading on Nasdaq as Obsidian Therapeutics under ticker OBX on 4 Aug 2026. Proceeds are expected to fund operations into H2 2028.
Obsidian Therapeutics, Inc. (OBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of
